Many thanks. One question for Deborah and the second for Hal. So, Deborah the translocation inhibitor that you're about to take into the clinic for HIV, you highlighted as one of the long-term growth strategies. How confident are you in the freedom to operate on the intellectual property, ...
When Hoos first landed at GSK in 2012, generation two of immuno-oncology R&D was well underway, which resulted in approvals of a wave of programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1)-blocking antibodies, as well as the bi-specific antibody blinatumomab, the oncolytic virus...
and initial preclinical investigations on a potent and selective small-molecule inhibitor for Mcl-1. Our design strategies, focused on structural alterations, aimed to boost the inhibitor's potency and physicochemical characteristics, all while reducing the risk of functional cardiotoxicity. The newly dev...
PD1 + PARPi synergy – Estimated patient population of ~3k* Ovarian 1L – FIRST – Potential for PD1 + PARPi synergy – Estimated patient population of ~26k* Pivotal data readout expected 2023 Pivotal data readout expected 2023 Four pivotal studies to expand the potential value of Zejula ...
热销产品:Pentagastrin|Lupeol|Clopidogrel (hydrogen sulfate)|Hinokiflavone|Risdiplam|PD150606|3-Pyridineacetic acid|Zidovudine|Tadalafil|Monomethyl fumarate Trending products:Recombinant Proteins|Bioactive Screening Libraries|Natural Products|Fluorescent Dye|PROTAC|Isotope-Labeled Compounds|Oligonucleotides ...
GSK2656157, a PERK inhibitor, reduced LPS-induced IL-1β production through inhibiting Caspase 1 activation in macrophage-like J774.1 cells. Immunopharmacol Immunotoxicol. 2016 Aug;38(4):298-302.[4]. Zhao Q, et al. Thioredoxin-interacting protein links endoplasmic reticulum stress to inflammatory...
Combining GSK3377794 with an anti-PD1 inhibitor (pembrolizumab) may have synergistic antitumor activity. Objective Evaluate safety and efficacy of GSK3377794 alone or in combination with pembrolizumab in pts with relapsed MM. Methods This is an open-label, pilot study (NCT03168438) of GSK3377794 in...
In turn, GSK3 collaborates with CK2 to inactivate protein phosphatase inhibitor-2 (PPI2), a negative regulator of PP1 [[23], [24], [25], [26]]. Thus, GSK3 attenuates the inhibition of PP1, thereby enhancing its own activity through a positive feedback loop [27]. In addition, CK2...
Treatment with anti-PD1 antibodies improves survival in many cancers, but efforts to harness its benefit in mCRPC have been unsuccessful. In preclinical PTEN loss models, selective PI3K尾 inhibitor enhanced survival and the frequency of intratumoral T cells. We hypothesized that the combination of ...
inhibitor relapsed/ refractory patients relapsed/ refractory patients '916 monotherapy, single arm, n=73 '916 monotherapy, single arm, n=155 '916 monotherapy vs. PomDex, n=320 '916 + PD1 combination, single arm, n=40 '916 + novel combinations, n=245 Study start Est launch 2014 ✓ --...